# US 2025/0144246 A1 · Compositions and methods for modifying a human dystrophin gene

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144246 A1
- Document ID: US20250144246A1
- Status: Published application
- Kind: A1
- Application number: 18/919,415
- Filed: 2024-10-17
- Published: 2025-05-08
- Earliest claimed: 2022-04-22
- Assignees: Mammoth Biosciences, Inc.
- Applicants: Mammoth Biosciences, Inc.
- Inventors: Lucas Benjamin HARRINGTON; Wiputra Jaya HARTONO; Pei-Qi LIU; Darren Bo Yee LO; Renan B. SPER
- Web page: https://patentgrep.com/patent/US20250144246A1

## CPC

- A61K 48/0058: {Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C07K 14/4708: {Duchenne dystrophy}
- C12N 9/1276: {RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/102: {Mutagenizing nucleic acids}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/86: Viral vectors
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2320/33: Alteration of splicing
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2840/20: translation of more than one cistron
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided herein are compositions, systems, and methods comprising effector proteins and uses thereof. These effector proteins may be characterized as CRISPR-associated (Cas) proteins. Various compositions, systems, and methods of the present disclosure may leverage the activities of these effector proteins for the modification, detection, and engineering of nucleic acids.

## Claims

### Claim 1

A composition that comprises:
(a) an effector protein comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 1, or a nucleic acid encoding the same, and
(b) a guide nucleic acid that comprises a spacer sequence that hybridizes to a target sequence of a human dystrophin (DMD) locus, or a nucleic acid encoding the same.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the guide nucleic acid comprises a nucleotide sequence that is at least 90% identical to SEO ID NO: 441 or a nucleotide sequence that is at least 90% identical to SEO ID NO: 443.

### Claim at position 3

-7. (canceled)

### Claim 8 (depends on 1)

The composition of claim 1, wherein the spacer sequence comprises a nucleotide sequence that is at least 90% identical to any one of SEQ ID NOs: 5-222.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the guide nucleic acid comprises a nucleotide sequence that is at least 90% identical to any one of SEQ ID NOs: 223-440.

### Claim 10 (depends on 1)

The composition of claim 1, wherein the effector protein comprises an amino acid sequence that is at least 95% identical to SEO ID NO: 1.

### Claim 11 (depends on 10)

The composition of claim 10, wherein the effector protein recognizes a protospacer adjacent motif (PAM) sequence recited in TABLE 2 or TABLE 25.

### Claim at position 8

-15. (canceled)

### Claim 16 (depends on 1)

The composition of claim 1, comprising a partner protein or a nucleic acid encoding the same.

### Claim 17 (depends on 16)

The composition of claim 16, wherein partner protein is fused or linked to the effector protein.

### Claim 18 (depends on 16)

The composition of claim 16, wherein the partner protein comprises a reverse transcriptase (RT) or a functional domain thereof.

### Claim at position 12

-38. (canceled)

### Claim 39 (depends on 18)

The composition of claim 18, wherein the RT is not fused or linked to the effector protein.

### Claim 40 (depends on 19)

The composition of claim 19, wherein the RT is fused or linked to an aptamer binding protein and wherein the guide nucleic acid comprises an aptamer.

### Claim 41 (depends on 11)

The composition of claim 11, comprising a template RNA.

### Claim 42 (depends on 1)

The composition of claim 1, wherein the nucleic acid encoding the effector protein and the nucleic acid encoding the guide nucleic acid are located in a nucleic acid expression vector.

### Claim 43 (depends on 42)

The composition of claim 42, wherein the nucleic acid expression vector is an adeno associated viral (AAV) vector.

### Claim 44 (depends on 1)

A method of modifying a human dystrophin gene (DMD), the method comprising contacting DMD with the composition of claim 1.

### Claim 45 (depends on 1)

A cell comprising the composition of claim 1 or modified by the composition of claim 1.

### Claim 46 (depends on 45)

The cell of claim 45, wherein the cell is a cardiac muscle cell, a cardiomyocyte, a myocyte, a smooth muscle cell, a skeletal muscle cell, or a visceral muscle cell.

### Claim 47 (depends on 1)

A method of treating a disease associated with a mutation or aberrant expression of DMD in a human subject in need thereof, the method comprising administering to the human subject the composition of claim 1.
